UBS PT reduces Enovis Corporation (ENOV) to $ 57 from $ 65, keeps a purchase classification

Enovis (NYSE:EnovHe is one of The best shares of the medical device for purchase according to analysts. On August 8, UBS reduced the company’s price goal on Enovis Corporation (NYSE: Enov) to $ 57 from $ 65, while maintaining the purchase rating on shares.

A patient receives cold treatment using the company’s products.

The classification update came after Enovis Corporation (NYSE: Enov) reported the financial profits of Q2 2025 on August 7, when quarter -sales reached $ 565 million, which reflects 7 % growth on the basis of reported and 5 % on an organic basis compared to the same quarter last year.

The administration stated that the financial Q2 financial results reflect the stable markets, the continuous implementation of the P&R and Recon, and the positive momentum in the introductions of the new product.

Enovis Corporation (NYSE: ENOV) is a growth company for a medical technology that develops clinically different solutions to transform the workflow and generate better results for the patient. The company operates through segments of prevention, recovery and restoration.

While we acknowledge the capabilities of ENOV as an investment, we believe that some artificial intelligence shares provide greater potential in the upward trend and carry less risks on the downside. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 30 stocks must double in 3 years and 11 stocks of hidden artificial intelligence for purchase now.

Detection: Nothing. This article was originally published in A monkey from the inside.